Yasukawa M, Shiroguchi T, Inatsuki A, Kobayashi Y
First Department of Internal Medicine, Ehime University School of Medicine, Japan.
Blood. 1988 Jul;72(1):102-8.
The ability of B-cell chronic lymphocytic leukemia (B-CLL) cells to present antigen to antigen-specific T cells was investigated. B-CLL cells present herpes simplex virus (HSV) antigen and purified protein derivative (PPD) to HSV- and PPD-specific, interleukin-2-dependent T-cell lines in an antigen-specific manner. Treatment of B-CLL cells with the phorbol ester 12-O-tetradecanoylphorbol-13-acetate (TPA) induced markedly increased levels of HLA-DR expression. TPA-treated B-CLL cells showed substantially more effective presentation, especially at low antigen concentrations, than did untreated B-CLL cells. By coculturing different allogeneic combinations of B-CLL cells and T cells and by adding anti-HLA-DR monoclonal antibody to cultures, it was found that antigen presentation by B-CLL cells was restricted by HLA-DR in the same way as for macrophages. We concluded from these experiments that B-CLL cells have a capacity to serve as antigen-presenting cells in an HLA class II-restricted fashion and that increasing the amount of HLA class II antigen and activation of B-CLL cells resulted in effective antigen presentation.
对B细胞慢性淋巴细胞白血病(B-CLL)细胞向抗原特异性T细胞呈递抗原的能力进行了研究。B-CLL细胞以抗原特异性方式向单纯疱疹病毒(HSV)特异性和纯化蛋白衍生物(PPD)特异性、白细胞介素-2依赖的T细胞系呈递HSV抗原和PPD。用佛波酯12-O-十四酰佛波醇-13-乙酸酯(TPA)处理B-CLL细胞可显著提高HLA-DR表达水平。与未处理的B-CLL细胞相比,经TPA处理的B-CLL细胞,尤其是在低抗原浓度下,表现出更有效的呈递。通过共培养B-CLL细胞和T细胞的不同同种异体组合,并向培养物中添加抗HLA-DR单克隆抗体,发现B-CLL细胞的抗原呈递与巨噬细胞一样受到HLA-DR的限制。我们从这些实验得出结论,B-CLL细胞有能力以HLA II类限制的方式作为抗原呈递细胞,并且增加HLA II类抗原的量和激活B-CLL细胞会导致有效的抗原呈递。